- Paul J. Hergenrother, PhD, Founder, Director, CSO
The procaspase 3 activation technology was invented in Professor Hergenrother’s laboratory, and he serves as the Company’s Chief Scientific Officer and as a Director. Paul provides key scientific and technical expertise to the Company’s development efforts and leads all research activities. Paul is the Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry and Professor of Chemistry at the University of Illinois, Urbana-Champaign.
- Tim Fan, PhD, DVM, VP Preclinical Development
Tim provides the company with extensive pre-clinical in vivo testing, small animal internal medicine, medical oncology and tumor immunology expertise. He is also a Principal investigator of the Comparative Oncology Research Laboratory and Professor of Veterinary Clinical Medicine at the University of Illinois.
- Ted Tarasow, PhD, Founder, Director, CEO
Ted serves as a Director and as Vanquish’s Chief Executive Officer providing overall management leadership for the Company’s development program. Ted has 20 years of R&D and Operations management experience in Biotech Rx and Dx organizations; including leading successful multidisciplinary teams to research, develop and launch innovative new products. Ted has held senior management roles at Tethys Bioscience, Lawrence Livermore National Laboratory, Replidyne, Invenux (Founder) and NeXstar Pharmaceuticals.
- Arek Dudek, MD, PhD, Clinical Advisor, Chairman Clinical Advisory Board
Arek serves as the Company’s Clinical Advisory Board Chairman. He brings to Vanquish over 15 years of cancer clinical research experience, over 15 years in clinical management of thoracic, skin, and urologic cancers, and over 10 years in the field of endothelial cell biology, tumor angiogenesis, and cancer immunotherapy, and over 5 years in anticancer drug development. Arek is a Professor in the College of Medicine at the University of Illinois, Chicago and serves as the Head of the Clinical Trial Office of University of Illinois Cancer Center and a Phase 1 Unit for Cancer Therapeutics.
Board of Directors
- Paul Hergenrother, Founder, Director, CSO
- Ted Tarasow, Founder, Director, CEO
- Ron Way, Director